Program
cilofexor
Also written as “Cilofexor”, “CILO” and “Cilofexor Dose B”.
Its studies are mostly in Non-alcoholic Fatty Liver Disease · Cholangitis, Sclerosing · Liver Cirrhosis, Biliary, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 121 open or running | phase 3since Mar 25, 2019 | Jan 11, 2016 | Dec 2028phase 2 · NCT07841977 |
| Phenex Pharmaceuticals | 10 open or running | phase 2since Nov 19, 2013 | Nov 19, 2013 | none ahead |
Also a collaborator on its studies: Novo Nordisk.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 19, 2013First study: phase 2 study in Non-alcoholic Fatty Liver DiseaseNew to Phenex PharmaceuticalsPhenex Pharmaceuticals · NCT01999101 · 12 enrolled · Austria
- Jan 11, 2016Gilead Sciences's first study: phase 1 study in Non-alcoholic Fatty Liver DiseaseNew to Gilead SciencesGilead Sciences · NCT02654002 · 120 enrolled · United States
- May 20, 2016Phase 2 study in Non-alcoholic Fatty Liver DiseaseGilead Sciences · NCT02781584 · 220 enrolled · United States, New Zealand
- Jun 13, 20162 phase 2 studiesGilead Sciences · NCT02943460, NCT02943447
- Jun 17, 2016Phase 1 study in Non-alcoholic Fatty Liver DiseaseGilead Sciences · NCT02808312 · 57 enrolled · United States, New Zealand
- Jul 29, 2016Phase 2 study in Non-alcoholic Fatty Liver DiseaseGilead Sciences · NCT02854605 · 140 enrolled · United States, Canada, Hong Kong and more
- Feb 23, 2018Phase 2 study in Non-alcoholic Fatty Liver DiseaseGilead Sciences · NCT03449446 · 395 enrolled · United States, Australia, Canada and more
- Mar 25, 2019Phase 3 study in Cholangitis, SclerosingGilead Sciences · NCT03890120 · 419 enrolled · United States, Australia, Austria and more
- Jun 12, 2019Phase 2 study in Non-alcoholic Fatty Liver DiseaseGilead Sciences · NCT03987074 · 109 enrolled · United States
- Aug 15, 2019Phase 1 study in Cholangitis, SclerosingGilead Sciences · NCT04060147 · 11 enrolled · United States
- Jul 20, 2021Phase 2 study in Non-alcoholic Fatty Liver DiseaseGilead Sciences · NCT04971785 · 457 enrolled · United States, Australia, Canada and more
- Sep 21, 2026Phase 2 study in Liver Cirrhosis, BiliaryGilead Sciences · NCT07841977 · 132 planned · United States
Ahead
- Dec 2028Primary completion: phase 2 study in Liver Cirrhosis, BiliaryGilead Sciences · NCT07841977
TargetBeta
“Bile acid receptor FXR agonist”ChEMBL 37, by rule
Other programs on NR1H4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| LY4395089 | Eli Lilly | phase 2 | 3 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07841977Liver Cirrhosis, Biliary · United States | 2 | Recruiting | Gilead Sciences | Dec 2028 | 132 |
| NCT04971785Non-alcoholic Fatty Liver Disease · United States, Australia, Canada and more | 2 | Completed | Gilead Sciences | Nov 12, 2024 | 457 |
| NCT04060147Cholangitis, Sclerosing · United States | 1 | Terminated | Gilead Sciences | Sep 2, 2021 | 11 |
| NCT03987074Non-alcoholic Fatty Liver Disease · United States | 2 | Completed | Gilead Sciences | Jul 13, 2020 | 109 |
| NCT03890120Cholangitis, Sclerosing · United States, Australia, Austria and more | 3 | Terminated | Gilead Sciences | Nov 10, 2022 | 419 |
| NCT03449446Non-alcoholic Fatty Liver Disease · United States, Australia, Canada and more | 2 | Completed | Gilead Sciences | Oct 30, 2019 | 395 |
| NCT02854605Non-alcoholic Fatty Liver Disease · United States, Canada, Hong Kong and more | 2 | Completed | Gilead Sciences | Jan 9, 2018 | 140 |
| NCT02808312Non-alcoholic Fatty Liver Disease · United States, New Zealand | 1 | Completed | Gilead Sciences | Oct 16, 2018 | 57 |
| NCT02943460Cholangitis, Sclerosing · United States, Austria, Canada and more | 2 | Completed | Gilead Sciences | Feb 28, 2018 | 52 |
| NCT02943447Liver Cirrhosis, Biliary · United States, Austria, Canada and more | 2 | Terminated | Gilead Sciences | Sep 4, 2019 | 71 |
| NCT02781584Non-alcoholic Fatty Liver Disease · United States, New Zealand | 2 | Completed | Gilead Sciences | Dec 17, 2020 | 220 |
| NCT02654002Non-alcoholic Fatty Liver Disease · United States | 1 | Completed | Gilead Sciences | Jul 14, 2016 | 120 |
| NCT01999101Non-alcoholic Fatty Liver Disease · Austria | 2 | Completed | Phenex Pharmaceuticals | Jan 2015 | 12 |
How it is read
Names in the registry
- “Cilofexor”, 7 entries
- “CILO”, 2 entries
- “Cilofexor Dose B”, 1 entry
- “Cilofexor Dose A”, 1 entry
- “Cilofexor (CILO)/Firsocostat (FIR)”, 1 entry
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 8 studies
- Cholangitis, Sclerosing, 3 studies
- Liver Cirrhosis, Biliary, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.